臺灣博碩士論文加值系統

目錄
指導教授推薦書 ............................................
口試委員會審定書 ..........................................
誌謝 .................................................. iii
中文摘要 ................................................ v
Abstract .......................................................... vii
目錄 .................................................. x
圖目錄 .................................................. xiii
表目錄 ................................................ xv
第一章 緒論 ............................................................................................ 1
第一節 研究動機與重要性 ............................................................ 1
第二節 研究目的 ............................................................................ 3
第三節 研究問題 ............................................................................ 3
第四節 名詞解釋 ............................................................................ 4
第二章 文獻查證 ................................................................................. 5
第一節 乳癌治療與認知功能 ........................................................ 5
第二節 認知功能測量 .................................................................... 8
第三節 最佳截切點及最小臨床重要差異值之介紹 ................... 12
第三章 研究方法 ............................................................................ 20
第一節 研究架構 .......................................................................... 20
第二節 研究設計 .......................................................................... 21
第三節 研究場所與對象 .............................................................. 22
第四節 研究工具 .......................................................................... 23
第五節 資料收集過程 .................................................................. 31
第六節 資料統計與分析 .............................................................. 34
第七節 樣本估計 .......................................................................... 36
第八節 倫理考量 .......................................................................... 37
第四章 研究結果與分析 ................................................................. 38
第一節 最佳截切點之估計 .......................................................... 40
一、基本人口學資料 ............................................................... 40
二、疾病相關資料 ................................................................... 44
三、認知功能部分之描述性統計資料 .................................... 48
四、最佳截切點估計 ............................................................... 50
五、HSCS-C自我調節與計畫次量表與類別、算術測驗間之比較 ............................................................................................. 62
第二節 最小臨床重要差異值之估計 .......................................... 65
一、基本人口學資料 ............................................................... 65
二、疾病相關資料 ................................................................... 69
三、最小臨床重要差異值之估計 ........................................... 73
第五章 討論 ..........................................................…......................... 81
第一節 最佳截切點之估計 .......................................................... 81
第二節 最小臨床重要差異值之估計 .......................................... 83
第六章 結論與建議 ......................................................................... 87
第一節 結論 .................................................................................. 87
第二節 臨床應用 .......................................................................... 88
第三節 研究限制與建議 .............................................................. 89
參考文獻 ............................................................................................... 91
附錄一 乳癌病人基本資料表............................................................. 102
附錄二 HSCS-C ................................................................................... 107
附錄三 GRC ........................................................................................ 118
附錄四 MMSE ..................................................................................... 119
附錄五 NP Tests .................................................................................. 122
 
圖目錄
圖3-1 Study1之收案流程圖 ................................................................. 32
圖3-2 Study2之收案流程圖 ................................................................. 32
圖4-1 Study2收案過程圖 ..................................................................... 39
圖4-1 HSCS-C視覺運動次量表各截切點所繪之ROC Curve（依分齡常模為標準） .......................................................................................... 51
圖4-2 HSCS-C視覺運動次量表各截切點所繪之ROC Curve （依45~54歲年齡層常模為標準） ............................................................... 52
圖4-3 HSCS-C空間次量表各截切點所繪之ROC Curve（依分齡常模為標準） .................................................................................................. 54
圖4-4 HSCS-C空間次量表各截切點所繪之ROC Curve（依45~54歲年齡層常模為標準） .............................................................................. 55
圖4-5 HSCS-C自我調節與計畫次量表各截切點所繪之ROC Curve（依類同測驗分齡常模為標準） .................................................................. 57
圖4-6 HSCS-C自我調節與計畫次量表各截切點所繪之ROC Curve（依類同測驗45~54歲年齡層常模為標準） .............................................. 58
圖4-7 HSCS-C自我調節與計畫次量表各截切點所繪之ROC Curve（依算數測驗分齡常模為標準） .................................................................. 60
圖4-8 HSCS-C自我調節與計畫次量表各截切點所繪之ROC Curve（依算數測驗45~54歲年齡層常模為標準） .............................................. 61
圖4-9 HSCS-C自我調節與計畫次量表總分與類同測驗量表得分之散佈圖 ........................................................................................................ 63
圖4-10 HSCS-C自我調節與計畫次量表總分與算術測驗量表得分之散佈 ........................................................................................................ 64
圖4-11 HSCS-C記憶次量表與GRC之散佈圖 ................................... 75
圖4-12 HSCS-C語言次量表與GRC之散佈圖 ................................... 76
圖4-13 HSCS-C視覺運動次量表與GRC之散佈圖 ........................... 76
圖4-14 HSCS-C空間次量表與GRC之散佈圖 ................................... 77
圖4-15 HSCS-C注意力/集中力次量表與GRC之散佈圖 .................. 77
圖4-16 HSCS-C自我調節與計畫次量表與GRC之散佈圖 ............... 78
圖4-17 HSCS-C總分與GRC之散佈圖 ............................................... 78
 
表目錄
表3-1 HSCS-C各次量表與NP Tests相對應之測驗對照表 ............... 27
表3-2 Study1及Study2之收案時間表 ................................................. 33
表4-1 Study1基本人口學資料 ............................................................. 41
表4-2 Study1疾病相關資料 ................................................................. 45
表4-3 HSCS-C各層面結果之描述性統計 .......................................... 48
表4-4 NP Tests各測驗結果之描述性統計 .......................................... 49
表4-5 HSCS-C視覺運動次量表的各截切點之診斷效度（依分齡常模為標準） .................................................................................................. 51
表4-6 HSCS-C視覺運動次量表各截切點診斷效度（依45~54年齡層常模為標準） .......................................................................................... 52
表4-7 HSCS-C空間次量表的各截切點之診斷效度（依分齡常模為標準） .......................................................................................................... 54
表4-8 HSCS-C空間次量表各截切點診斷效度（依45~54年齡層常模為標準） .................................................................................................. 55
表4-9 HSCS-C自我調節與計畫次量表的各截切點之診斷效度（依類同測驗分齡常模為標準） ...................................................................... 57
表4-10 HSCS-C自我調節與計畫次量表各截切點診斷效度（依類同測驗45~54年齡層常模為標準） .............................................................. 58
表4-11HSCS-C自我調節與計畫次量表各截切點之診斷效度（依算數測驗分齡常模為標準） .......................................................................... 60
表4-12 HSCS-C自我調節與計畫次量表各截切點診斷效度（依算數測驗45~54歲年齡層常模為標準） .......................................................... 61
表4-13 HSCS-C自我調節與計畫次量表、類同測驗、算術測驗個案量表得分之次數分配表 ............................................................................ 62
表4-14 HSCS-C自我調節與計畫次量表得分分佈 ............................ 63
表4-15 Study2基本人口學資料 ........................................................... 66
表4-16 Study2疾病相關資料 ............................................................... 70
表4-17 HSCS-C各時間點之描述性統計結果 .................................... 73
表4-18 GRC與HSCS-C各次量表及總分之相關係數 ....................... 74
表4-19 GRC與MSAS-SF第31題及第32題之卡方檢定結果 .......... 79
表4-20 以分佈取向法所得之HSCS-C各層面及總分的MCID ......... 80

參考資料
王天苗、廖華芳（2007）．嬰幼兒綜合發展測驗之判定準確度及切截點分析．特殊教育研究學刊，32（2），1-15。
呂文賢、李雅珍、凃富籌、謝清麟（2013）．短版巴氏量表應用於中風患者之最小可偵測變化值及反應性．臺灣復健醫學雜誌，41（2），113-119。
呂文賢、劉靖琁、李秉家、謝清麟、李柏森（2009）．褚氏手部靈巧度測驗應用於精神分裂症個案的再測一致性與最小可偵測之變化值．臺灣職能治療研究與實務雜誌，5（2），93-101。
林斈府、莊岳泉、吳逸騹、黃文彥、趙祖怡（2009）．乳癌治療的新趨勢．腫瘤護理雜誌，9（S），19-35。
林家興、陳玉芳、葉雅馨、徐佳玲、孫正大（2008） “董氏憂鬱量表（大專版）”編製研究．測驗學刊，55（3），509-533。
林嘉慧、林麗英、吳杼芸、林瑞玲、張春梅（2006）．門診病人接受化學治療之症狀困擾與處置經驗．榮總護理，23（4），364-373。
林璟宏（2013）．乳癌的化學治療．臺灣醫學，17（4），404-411。
胡名霞（2010）．認知功能篩檢的新選擇－SLUMS介紹．長期照護雜誌，14（3），267-276。
莊岳泉、趙祖怡（2008）．乳癌的輔助性化療．中華民國癌症醫學會雜誌，24（2），112-120。
許慧珍（2007）．聽覺障礙學童之視覺動作功能表現探討（碩士論文）．國立成功大學。
郭俐妏（2011）．探討輔助性化療對乳癌婦女認知功能之影響（碩士論文）．長庚大學護理學研究所。
陳宇平、陳信昭、蔡政潔（2008）． “飲食態度量表－26題版”(EAT-26)本土最佳切點之探討－以台南市兩所高中為例．中華心理衛生學刊，21（4），379-405。
黃恢濤、張嘉慧、蔡沛潔、馮紀慈、葉啟信、王淑真…周佳燁（2012）．中風病人健康生活品質指標．臺灣醫學，16（1），65-71。
楊啟正、王瑋瀚、黃勝堅、花茂棽（2006）．中重度頭部創傷後之神經認知功能障礙．臨床心理學刊，3（2），68-75。
衛生署國民健康局（2008）．女性乳房癌症相對存活率．取自https://cris.bhp.doh.gov.tw/pagepub/Home.aspx
癌症登記小組（2009）．癌症登記年度報告．取自http://tcr.cph.ntu.edu.tw/uploadimages/CA15_LF98_20130227.pdf
謝佳容（2003）．老年人認知功能的指標測量與應用．醫護科技學刊，5（4），387-395。
謝德熾、陳立奇（2010）．乳癌治療之演進．北市醫學雜誌，7（3），313-322。
Wechsler, D. (2002)．魏氏成人智力量表第三版中文版指導手冊 (陳榮華、陳心怡譯)．台灣：中國行為科學社。（原著出版於1997）
Acevedo, S. F. (2012). Why, after chemotherapy, is it necessary to assess memory using translational testing? Breast Cancer: Basic and Clinical Research, 6(1), 181-190.
Ahles, T. A., &; Saykin, A. J. (2002). Breast cancer chemotherapy-related cognitive dysfunction. Clinical breast cancer, 3 Suppl 3, S84-90.
Ahles, T. A., &; Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer, 7(3), 192-201.
Alexandrov, Y. I., &; Sams, M. E. (2005). Emotion and consciousness: Ends of a continuum. Cognitive Brain Research, 25(2), 387-405.
Asher, A. (2011). Cognitive dysfunction among cancer survivors. American Journal of Physical Medicine and Rehabilitation, 90(SUPPL.5), S16-S26.
Azim, H. A., de Azambuja, E., Colozza, M., Bines, J., &; Piccart, M. J. (2011). Long-term toxic effects of adjuvant chemotherapy in breast cancer. Annals of Oncology, 22(9), 1939-1947.
Barton, D. L., Burger, K., Novotny, P. J., Fitch, T. R., Kohli, S., Soori, G., . . . Loprinzi, C. L. (2013). The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Supportive Care in Cancer, 21(4), 1185-1192.
Beckerman, H., Roebroeck, M. E., Lankhorst, G. J., Becher, J. G., Bezemer, P. D., &; Verbeek, A. L. M. (2001). Smallest real difference, a link between reproducibility and responsiveness. Quality of Life Research, 10(7), 571-578.
Brezden, C. B., Phillips, K. A., Abdolell, M., Bunston, T., &; Tannock, I. F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18(14), 2695-2701.
Burns, A., Brayne, C., &; Folstein, M. (1998). Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. M. Folstein, S. Folstein and P. McHugh, Journal of Psychiatric Research (1975) 12, 189-198. International Journal of Geriatric Psychiatry, 13(5), 285-294.
Cella, D., Hahn, E. A., &; Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Quality of Life Research, 11(3), 207-221.
Chen, J., Yan, J., &; Han, X. (2013). Dexmedetomidine may benefit cognitive function after laparoscopic cholecystectomy in elderly patients. Experimental and therapeutic medicine, 5(2), 489-494.
Chen, M. L., Miaskowski, C., Liu, L. N., &; Chen, S. C. (2012). Changes in perceived attentional function in women following breast cancer surgery. Breast Cancer Research and Treatment, 131(2), 599-606.
Cheung, Y. T., Tan, E. H. J., &; Chan, A. (2012). An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Supportive Care in Cancer, 20(7), 1361-1375.
Chow, E., Fan, G., Hadi, S., &; Filipczak, L. (2007). Symptom clusters in cancer patients with bone metastases. Supportive Care in Cancer, 15(9), 1035-1043.
Corn, B. W., Moughan, J., Knisely, J. P. S., Fox, S. W., Chakravarti, A., Yung, W. K. A., . . . Movsas, B. (2008). Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. International Journal of Radiation Oncology Biology Physics, 71(1), 71-78.
Crosby, R. D., Kolotkin, R. L., &; Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56(5), 395-407.
de Vet, H. C., Terwee, C. B., Ostelo, R. W., Beckerman, H., Knol, D. L., &; Bouter, L. M. (2006). Minimal changes in health status questionnaires: Distinction between minimally detectable change and minimally important change. Health and Quality of Life Outcomes, 4(54).
Downie, F. P., Mar Fan, H. G., Houédé-Tchen, N., Yi, Q., &; Tannock, I. F. (2006). Cognitive function, fatique, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psycho-Oncology, 15(10), 921-930.
Dutta, V. (2011). Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. Journal of Cancer Research and Therapeutics, 7(3), 264-269.
Faust, D., &; Fogel, B. S. (1989). The development and initial validation of a sensitive bedside cognitive screening test. Journal of Nervous and Mental Disease, 177(1), 25-31.
Fishel, M. L., Vasko, M. R., &; Kelley, M. R. (2007). DNA repair in neurons: So if they don't divide what's to repair? Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 614(1-2), 24-36.
Fogel, B. S. (1991). The high sensitivity cognitive screen. International psychogeriatrics / IPA, 3(2), 273-288.
Folstein, M. F., Folstein, S. E., &; McHugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198.
Gangloff, A., Hsueh, W. A., Kesner, A. L., Kiesewetter, D. O., Pio, B. S., Pegram, M. D., . . . Silverman, D. H. S. (2005). Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 18F-fluoropaclitaxel. Journal of Nuclear Medicine, 46(11), 1866-1871.
Grober, S. E. (2002). Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Practice, 10(4), 216-218.
Guyatt, G. H., Bombardier, C., &; Tugwell, P. X. (1986). Measuring disease-specific quality of life in clinical trials. Canadian Medical Association Journal, 134(8), 889-895.
Hägg, O., Fritzell, P., &; Nordwall, A. (2003). The clinical importance of changes in outcome scores after treatment for chronic low back pain. European Spine Journal, 12(1), 12-20.
Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Proschel, M., &; Noble, M. (2008). Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Journal of Biology, 7(12), 12.11-12.22.
Hofmann, W., Schmeichel, B. J., &; Baddeley, A. D. (2012). Executive functions and self-regulation. Trends in Cognitive Sciences, 16(3), 174-180.
Hsieh, Y. W., Wang, C. H., Wu, S. C., Chen, P. C., Sheu, C. F., &; Hsieh, C. L. (2007). Establishing the minimal clinically important difference of the barthel index in stroke patients. Neurorehabilitation and Neural Repair, 21(3), 233-238.
Jaeschke, R., Singer, J., &; Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407-415.
Jansen, C. E., Miaskowski, C. A., Dodd, M. J., &; Dowling, G. A. (2007). A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncology Nursing Forum, 34(5), 997-1005.
Jansen, C. E., Miaskowski, C., Dodd, M., Dowling, G., &; Kramer, J. (2005). A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer, 104(10), 2222-2233.
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., . . . Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94(6), 828-834.
Joly, F., Rigal, O., Noal, S., &; Giffard, B. (2011). Cognitive dysfunction and cancer: Which consequences in terms of disease management? Psycho-Oncology, 20(12), 1251-1258.
Kamper, S. J., Maher, C. G., &; Mackay, G. (2009). Global rating of change scales: A review of strengths and weaknesses and considerations for design. Journal of Manual and Manipulative Therapy, 17(3), 163-170.
Kazis, L. E., Anderson, J. J., &; Meenan, R. F. (1989). Effect sizes for interpreting changes in health status. Medical Care, 27(3 Suppl), S178-189.
Lin, K. C., Hsieh, Y. W., Wu, C. Y., Chen, C. L., Jang, Y., &; Liu, J. S. (2009). Minimal detectable change and clinically important difference of the wolf motor function test in stroke patients. Neurorehabilitation and Neural Repair, 23(5), 429-434.
Lin, R., Zhang, F., Xue, Q., &; Yu, B. (2013). Accuracy of regional cerebral oxygen saturation in predicting postoperative cognitive dysfunction after total hip arthroplasty: Regional cerebral oxygen saturation predicts POCD. Journal of Arthroplasty, 28(3), 494-497.
Mar Fan, H. G., Clemons, M., Xu, W., Chemerynsky, I., Breunis, H., Braganza, S., &; Tannock, I. F. (2008). A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Supportive Care in Cancer, 16(6), 577-583.
McHorney, C. A., &; Tarlov, A. R. (1995). Individual-patient monitoring in clinical practice: Are available health status surveys adequate? Quality of Life Research, 4(4), 293-307.
Mehnert, A., Scherwath, A., Schirmer, L., Schleimer, B., Petersen, C., Schulz-Kindermann, F., . . . Koch, U. (2007). The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Education and Counseling, 66(1), 108-118.
Miki, E., Kataoka, T., &; Okamura, H. (2013). Clinical usefulness of the Frontal Assessment Battery at bedside (FAB) for elderly cancer patients. Supportive Care in Cancer, 21(3), 857-862.
Pomykala, K. L., &; Silverman, D. H. S. (2012). Alterations in brain structure and function after chemotherapy for cancer. Future Neurology, 7(4), 443-452.
Raffa, R. B. (2013). Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment). Journal of Clinical Pharmacy and Therapeutics, 38(4), 265-268.
Redelmeier, D. A., Guyatt, G. H., &; Goldstein, R. S. (1996). Assessing the minimal important difference in symptoms: A comparison of two techniques. Journal of Clinical Epidemiology, 49(11), 1215-1219.
Samsa, G., Edelman, D., Rothman, M. L., Williams, G. R., Lipscomb, J., &; Matchar, D. (1999). Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics, 15(2), 141-155.
Scherling, C. S., Collins, B., MacKenzie, J., Bielajew, C., &; Smith, A. (2011). Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: An fMRI study. [Original Research]. Frontiers in Human Neuroscience, 5. doi: 10.3389/fnhum.2011.00122
Schilder, C. M. T., Seynaeve, C., Linn, S. C., Boogerd, W., Beex, L. V. A. M., Gundy, C. M., . . . Schagen, S. B. (2010). Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Critical Reviews in Oncology/Hematology, 76(2), 133-141.
Shilling, V., &; Jenkins, V. (2007). Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. European Journal of Oncology Nursing, 11(1), 6-15.
Tannock, I. F., Ahles, T. A., Ganz, P. A., &; van Dam, F. S. (2004). Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. Journal of Clinical Oncology, 22(11), 2233-2239.
Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., . . . Tannock, I. F. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21(22), 4175-4183.
Tombaugh, T. N. (2006). A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Archives of Clinical Neuropsychology, 21(1), 53-76.
Vardy, J., Wong, K., Yi, Q. L., Park, A., Maruff, P., Wagner, L., &; Tannock, I. F. (2006). Assessing cognitive function in cancer patients. Supportive Care in Cancer, 14(11), 1111-1118.
Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., &; Meyers, C. A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer, 100(11), 2292-2299.
Wilson, C. J., Finch, C. E., &; Cohen, H. J. (2002). Cytokines and cognition - The case for a head-to-toe inflammatory paradigm. Journal of the American Geriatrics Society, 50(12), 2041-2056.
Wolinsky, F. D., Wan, G. J., &; Tierney, W. M. (1998). Changes in the SF-36 in 12 Months in a Clinical Sample of Disadvantaged Older Adults. Medical Care, 36(11), 1589-1598.
Wyrwich, K. W., Bullinger, M., Aaronson, N., Hays, R. D., Patrick, D. L., &; Symonds, T. (2005). Estimating clinically significant differences in quality of life outcomes. Quality of Life Research, 14(2), 285-295.